


PHARMACEUTICAL 2020

Evolus Inc. Rank 159 of 362









PHARMACEUTICAL 2020

## Evolus Inc. Rank 159 of 362



The relative strengths and weaknesses of Evolus Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Evolus Inc. compared to the market average is the variable Research and Development, increasing the Economic Capital Ratio by 121% points. The greatest weakness of Evolus Inc. is the variable Selling, General and Administrative Expense, reducing the Economic Capital Ratio by 132% points.

The company's Economic Capital Ratio, given in the ranking table, is -139%, being 164% points above the market average of -303%.

Input Variable	Value in 1000 USD
Assets, Current	152,197
Cost of Goods Sold	8,014
Intangible Assets	80,846
Liabilities, Current	24,439
Liabilities, Non-Current	77,401
Other Assets	6,497
Other Compr. Net Income	6.0
Other Expenses	-6,735
Other Liabilities	59,145
Other Net Income	-6,114
Property and Equipment	902
Research and Development	3,973
Revenues	34,925
Selling, General and Administrative Expense	113,593

Output Variable	Value in 1000 USD
Assets	240,442
Liabilities	160,985
Expenses	118,845
Stockholders Equity	79,457
Net Income	-90,034
Comprehensive Net Income	-90,031
Economic Capital Ratio	-139%

